Tepezza vs Syfovre
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Tepezza | US Syfovre | |
|---|---|---|
| Generic name | teprotumumab | pegcetacoplan |
| Drug class | IGF-1R Inhibitor (Biologic) | Complement C3 Inhibitor |
| Treats | Thyroid eye disease | Geographic atrophy (advanced dry AMD) |
| Category | Eye Health | Eye Health |
| Manufacturer | Amgen | Apellis Pharmaceuticals |
| Year approved | 2020 | 2023 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | — | — |
| Common side effects | Muscle spasms, Nausea, Hair loss, Hearing problems | Eye discomfort, Floaters, Bleeding in the eye, Increased eye pressure |
Frequently asked questions
Is Tepezza or Syfovre better?
Neither is universally "better." Tepezza (teprotumumab) and Syfovre (pegcetacoplan) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Tepezza and Syfovre?
Tepezza is a IGF-1R Inhibitor (Biologic) made by Amgen, while Syfovre is a Complement C3 Inhibitor made by Apellis Pharmaceuticals. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Tepezza has the larger estimated TV advertising budget of the two.